Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update

被引：51
|
作者：
Ciarallo, Anthony [1 ]
Rivera, Juan [2 ]
机构：
[1] McGill Univ, Hlth Ctr, Dept Med Imaging, Div Nucl Med, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada
[2] McGill Univ, Hlth Ctr, Dept Med, Div Endocrinol & Metab, Montreal, PQ, Canada
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2020年 / 215卷 / 02期
关键词：
differentiated thyroid cancer; DTC; I-131; radioactive iodine therapy; RAI; thyroid cancer; RADIOIODINE-REMNANT ABLATION; I-131; METAANALYSIS; PATIENT;
D O I：
10.2214/AJR.19.22626
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OBJECTIVE. The paradigm of theranostics is based on tailoring therapy for the purpose of optimizing outcomes. This principle is being applied to radioactive iodine therapy. Consequently, thyroid cancer therapy protocols are evolving. The purpose of this article is to promote a modern approach to radioiodine therapy. CONCLUSION. This article highlights guidelines and position statements, summarizes the prognostication systems of thyroid cancer, and reviews which prescribed activities of I-131 are appropriate for each risk category.
引用
收藏
页码：285 / 291
页数：7
相关论文
共 50 条
  • [1] Radioactive iodine therapy in poorly differentiated thyroid cancer
    R Michael Tuttle
    Ravinder K Grewal
    Steve M Larson
    Nature Clinical Practice Oncology, 2007, 4 : 665 - 668
  • [2] Radioactive iodine therapy in poorly differentiated thyroid cancer
    Tuttle, R. Michael
    Grewal, Ravinder K.
    Larson, Steve M.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (11): : 665 - 668
  • [3] Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer
    Verburg, Frederik A.
    Haenscheid, Heribert
    Luster, Markus
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 31 (03) : 279 - 290
  • [4] Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies
    Nguyen, Nghi C.
    Anigati, Elena M.
    Desai, Neil B.
    Oz, Orhan K.
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 488 - 496
  • [5] Update on the systemic management of radioactive iodine refractory differentiated thyroid cancer (Review)
    Babu, Geethu
    Kainickal, Cessal Thommachan
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 14 (02) : 1 - 7
  • [6] Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
    Liu, Jierui
    Liu, Yanqing
    Lin, Yansong
    Liang, Jun
    ENDOCRINOLOGY AND METABOLISM, 2019, 34 (03) : 215 - 225
  • [7] Comparing therapeutic outcomes: radioactive iodine therapy versus non-radioactive iodine therapy in differentiated thyroid cancer
    Tiuca, Robert Aurelian
    Tiuca, Oana Mirela
    Pop, Raluca Monica
    Pascanu, Ionela Maria
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [8] Severe Hyponatremia Following Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer
    Kim, Seung Kyu
    Yun, Gi Young
    Kim, Ki Hyun
    Park, Seung Kyo
    Choi, Hoon Young
    Ha, Sung Kyu
    Park, Hyeong Cheon
    THYROID, 2014, 24 (04) : 773 - 777
  • [9] Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer
    Hong C.M.
    Ahn B.-C.
    Nuclear Medicine and Molecular Imaging, 2018, 52 (4) : 247 - 253
  • [10] Influence of radioactive iodine therapy on liver function in patients with differentiated thyroid cancer
    Wang, Sen
    Liang, Chao
    Zhao, Li
    Meng, Zhaowei
    Zhang, Chunmei
    Jia, Qiang
    Tan, Jian
    Yang, Hui
    Liu, Xiangxiang
    Wang, Xiaoran
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1113 - 1120
12345